Solara Active Pharma Sciences Limited

NSE SOLARA.NS

Solara Active Pharma Sciences Limited Revenue Per Share for the year ending March 31, 2024: USD 3.80

Solara Active Pharma Sciences Limited Revenue Per Share is USD 3.80 for the year ending March 31, 2024, a -22.11% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • Solara Active Pharma Sciences Limited Revenue Per Share for the year ending March 31, 2023 was USD 4.88, a 8.23% change year over year.
  • Solara Active Pharma Sciences Limited Revenue Per Share for the year ending March 31, 2022 was USD 4.51, a -32.76% change year over year.
  • Solara Active Pharma Sciences Limited Revenue Per Share for the year ending March 31, 2021 was USD 6.71, a 3.18% change year over year.
  • Solara Active Pharma Sciences Limited Revenue Per Share for the year ending March 31, 2020 was USD 6.50, a -15.65% change year over year.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
Loading...
NSE: SOLARA.NS

Solara Active Pharma Sciences Limited

CEO Mr. Poorvank Purohit
IPO Date June 27, 2018
Location India
Headquarters Admin Block 27
Employees 2,156
Sector Health Care
Industries
Description

Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India. The company offers APIs for anesthetics, anthelmintic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-viral, antibiotic, anticoagulant, anticonvulsant, antidepressant, antiemetic, antiepileptic, antifungal, antigout agent, antihistamine, antihyperlipoproteinemic, antimalarial, antimycotic, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antitussive, antiulcerative, anxiolytic, bile acid analogue, calcimimetic agent, cardiovascular agent, central nervous system agent, chronic alcoholism, chronic kidney disease, dopamine receptor antagonist, folate analog, hyperkalaemia, immunosuppressant, lipid regulating agent, loop diuretic, muscarinic agonist, neuromuscular, OAB treatment, phenylalanine reducer, recovery of stroke, tardive dyskinesia, treatment of glaucoma and hyperphosphatemia, tropical anti-infective, and type-II diabetes therapeutic categories. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support. In addition, the company exports its products. It operates in the Asia Pacific, Europe, North America, South America, and internationally. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.

Similar companies

AARTIDRUGS.NS

Aarti Drugs Limited

USD 4.85

-0.49%

SUVENPHAR.NS

Suven Pharmaceuticals Limited

USD 12.19

0.62%

SEQUENT.NS

Sequent Scientific Limited

USD 2.07

5.03%

JBCHEPHARM.NS

J. B. Chemicals & Pharmaceuticals Limited

USD 20.35

-1.23%

SHILPAMED.NS

Shilpa Medicare Limited

USD 9.00

6.34%

StockViz Staff

January 15, 2025

Any question? Send us an email